<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012387</url>
  </required_header>
  <id_info>
    <org_study_id>CUN-OMAL-UCOL</org_study_id>
    <nct_id>NCT02012387</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Omalizumab in Cholinergic Urticaria</brief_title>
  <acronym>CUN-OMAL-UCOL</acronym>
  <official_title>Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Joan XXIII de Tarragona.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complejo Hospitalario de Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario Lozano Blesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy and safety of Omalizumab in a new indication, that is cholinergic
      urticaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physical urticarias, such as delayed pressure, cholinergic, dermatographism and cold
      urticaria, are highly disabling conditions[1]. Cholinergic urticaria occurs due to an active
      (e.g. exercise) or passive (e.g. hot bath) increase in core body temperature, causing itching
      and small hives with flare reaction on the trunk and limps that fade away upon cooling of the
      body[2].

      As it is the case of chronic urticaria, physical urticarias have a great impact on patients'
      quality of life[3, 4]. However, these types of urticarias cause even more alteration on
      quality of life because of the limitations they cause in daily life activities, sports
      practicing[5] or work performance.

      In spite of the high morbidity of this disease and the impact on quality of life, there is no
      available treatment. Antihistamines that usually control other types of urticaria could only
      partially alleviate cholinergic urticaria. There is only one paper[6] that shows efficacy
      doubling the dose of cetirizine above the recommended dosage on the Summary of Product
      Characteristics (off-label dosage). The poor response to antihistamine is justified by the
      minimal role of histamine in its physiopathology and only after employing very high doses[7].

      The etiology and pathogenesis of hive formation remains unknown, though it is recognized that
      mast cells are clearly involved[8]. On the other hand, it seems that desensitization or
      tolerance could be induced in cholinergic urticaria[9]. Thus as it is the case of drug
      desensitization, Immunoglobulin E (IgE) receptor must also play a role in the development of
      this physical urticaria[10].

      In the past years, the monoclonal humanized anti-IgE antibody (Omalizumab) was shown to be
      effective in control cholinergic urticaria[11] not respondent to conventional therapies at
      maximum or off-label doses. A negative response was also reported for cholinergic
      urticaria[12].

      Our rationale for this approach in this type of urticaria is that Omalizumab exerts an
      inhibitory action on mast cell activation, as is the case of desensitization.

      For that purpose, we will perform a multicenter, randomized, double-blind, placebo-controlled
      parallel clinical trial. We will include 24 patients including both female and male patients
      (age 14 years or older), non-respondent to antihistamines.

      Efficacy will be evaluated through the negativization of the European Academy of Allergy and
      Clinical Immunology (EAACI), European Dermatology Forum (EDF) and urticaria network e.V
      (UNEV) standardized exercise challenge test, Visual Analog Scale (VAS), Chronic Urticaria
      Quality of Life validated questionnaire[13], patients' card of symptoms and use of rescue
      medication. Additional measures of efficacy will also be: the number of dropouts in each
      treatment group; the leave days due of urticaria and Emergency Department visits. Finally,
      safety will be assessed by means of recording and evaluation of adverse reactions during
      treatment.

      As we previously stated, Omalizumab is not indicated for physical or other types of
      urticaria. The only indication is for treatment of moderate-to-severe allergic asthma. The
      hypothesis we are working on is that the monoclonal anti-IgE antibody Omalizumab could be as
      well effective in controlling physical urticaria symptoms in patients non-respondent to
      conventional therapy. We hypothesize that Omalizumab is able to revert the basophil or mast
      cell activation present in those urticaria types.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negativization of the exercise challenge test</measure>
    <time_frame>It will be assessed prior to the study, and subsequently each 4 weeks up to 12 months.</time_frame>
    <description>a. Our primary endpoint will be the negativization of the exercise challenge test: We will perform the exercise challenge test following the European Guidelines[14] for cholinergic urticaria. According with such guidelines, all centers will follow the same center standardized protocol. The patient will exercise in treadmill or running to the point of sweating and following for 15 more minutes, wearing warm clothing in a warm room. The test will be considered positive if exercise challenge leads to the typical rash over 10 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>It will be evaluated up to 48 weeks.</time_frame>
    <description>Quality of Life: QoL will be evaluated through the Spanish validated version of Chronic Urticaria quality of life (CU-Q2oL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' card</measure>
    <time_frame>It will be assessed up to 48 weeks.</time_frame>
    <description>Use of medication, VAS, daily symptoms, emergency visits, days off work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment drop offs in each sequence</measure>
    <time_frame>Up to 48 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cholinergic Urticaria</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open labeled</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the double blinded period, all patients from both arms will receive the active drug for 8 more months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Biological/Vaccine: Omalizumab</other_name>
    <other_name>Other Names:</other_name>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Biological/Vaccine: Placebo</other_name>
    <other_name>Other Names: Saline serum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Open labeled</intervention_name>
    <description>Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks</description>
    <arm_group_label>Open labeled</arm_group_label>
    <other_name>Biological: Omalizumab</other_name>
    <other_name>Other Names:</other_name>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult female and male patients (age 14 years or older). Diagnosis of cholinergic urticaria
        trough clinical history and positive challenge test.

        Non-respondent to supra therapeutic doses of antihistamines (defined as 2x the maximal dose
        included in the drug labeling) Written informed consent.

        Exclusion Criteria:

        Pruritus related to dermatitis or other skin condition. Any systemic disease that hampers
        follow up or interpretation of data. Omalizumab treatment within the previous 12 months.
        Any exclusion criteria included in the drug labeling. Any other conditions that do not
        allow the accomplishment of the clinical trial requisites, such as the abuse of drugs or
        alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Departamento de Alergología. Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Abajian M, Młynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep. 2012 Aug;12(4):281-7. doi: 10.1007/s11882-012-0269-0. Review.</citation>
    <PMID>22653630</PMID>
  </reference>
  <reference>
    <citation>Hirschmann JV, Lawlor F, English JS, Louback JB, Winkelmann RK, Greaves MW. Cholinergic urticaria. A clinical and histologic study. Arch Dermatol. 1987 Apr;123(4):462-7.</citation>
    <PMID>3827277</PMID>
  </reference>
  <reference>
    <citation>O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997 Feb;136(2):197-201.</citation>
    <PMID>9068731</PMID>
  </reference>
  <reference>
    <citation>Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, Braido F, Majani G, Canonica GW. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003 Jul;58(7):621-3.</citation>
    <PMID>12823121</PMID>
  </reference>
  <reference>
    <citation>Tlougan BE, Mancini AJ, Mandell JA, Cohen DE, Sanchez MR. Skin conditions in figure skaters, ice-hockey players and speed skaters: part II - cold-induced, infectious and inflammatory dermatoses. Sports Med. 2011 Nov 1;41(11):967-84. doi: 10.2165/11592190-000000000-00000. Review.</citation>
    <PMID>21985216</PMID>
  </reference>
  <reference>
    <citation>Zuberbier T, Münzberger C, Haustein U, Trippas E, Burtin B, Mariz SD, Henz BM. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193(4):324-7.</citation>
    <PMID>8993958</PMID>
  </reference>
  <reference>
    <citation>Nakamizo S, Egawa G, Miyachi Y, Kabashima K. Cholinergic urticaria: pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):114-6. doi: 10.1111/j.1468-3083.2011.04017.x. Epub 2011 Mar 4. Review.</citation>
    <PMID>21371134</PMID>
  </reference>
  <reference>
    <citation>Haas N, Toppe E, Henz BM. Microscopic morphology of different types of urticaria. Arch Dermatol. 1998 Jan;134(1):41-6.</citation>
    <PMID>9449908</PMID>
  </reference>
  <reference>
    <citation>Kozaru T, Fukunaga A, Taguchi K, Ogura K, Nagano T, Oka M, Horikawa T, Nishigori C. Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int. 2011 Sep;60(3):277-81. doi: 10.2332/allergolint.10-OA-0269. Epub 2011 Feb 25.</citation>
    <PMID>21364312</PMID>
  </reference>
  <reference>
    <citation>Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005 May;94(5):575-80.</citation>
    <PMID>15945561</PMID>
  </reference>
  <reference>
    <citation>Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, Siebenhaar F, Weller K, Zuberbier T, Maurer M. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177-80. doi: 10.1159/000320233. Epub 2010 Aug 24.</citation>
    <PMID>20733327</PMID>
  </reference>
  <reference>
    <citation>Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol. 2010 Jun;35(4):e127-9. doi: 10.1111/j.1365-2230.2009.03748.x. Epub 2009 Nov 19.</citation>
    <PMID>19925484</PMID>
  </reference>
  <reference>
    <citation>Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, Braga M, Lombardi C, Fassio O, Canonica GW. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005 Aug;60(8):1073-8.</citation>
    <PMID>15969690</PMID>
  </reference>
  <reference>
    <citation>Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214-20.</citation>
    <PMID>15552715</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholinergic urticaria</keyword>
  <keyword>Omalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

